Search 

PSites Pharma is developing the next generation of protein kinase inhibitors. Based on our discovery of a new non-ATP competitive, regulatory  binding site we had build up during the last 12 years a whole proprietary development platform, consisting of a focused library, a special screening and a crystallography platform. This allows us to develop clinical candidates for kinase inhibitors with specificities unknown for small coumpounds for any given ACG kinase target within 3 years.

Psites´s own lead compounds for oncology indications (lung and prostate cancer) had been successfully tested in mice and show a very good safety profile.

Our next financing round which is supported by a EUR 3 M. grant by the German governement will enable us to bring 2 compounds into the clinic and we are looking for partners who will share part of the development costs.

Alternatively we are also offering development collaborations for industrial partners who are interested in getting allosteric compounds for their specific target.